To further investigate how aberrant JAK/STAT3 signaling modulates the sensitivity of EGFR-mutant NSCLC cells to EGFR-TKIs, we evaluated pharmacological and genetic interventions. This evidence concerns the gene EGFR and non-small cell lung carcinoma.